Company Profile
Alkermes plc Stock Price, News & Analysis
Company overview
Business overview
Alkermes plc is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Alkermes plc is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Alkermes plc follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Alkermes plc sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
ALKS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Alkermes’ catalysts are VIVITROL, Lybalvi, and any CNS pipeline update that broadens the company’s growth mix. Investors will watch whether the commercial base stays durable.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
Source: Alkermes plc
- 03
Alkermes plc Announces CEO Succession Plan
Source: Alkermes plc
- 04
- 05
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
Source: Alkermes plc
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.